Wall Street analyst estimates for Stryker Corporation (SYK): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries.
Analyst Consensus
| Strong Buy | 1 |
| Buy | 37 |
| Hold | 14 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 52 |
| Avg rating (1-5) | 0.75 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-10-29 | $3.62 | ||
| 2026-07-30 | $3.69 | $3.49 | +5.7% |
| 2026-04-30 | $2.60 | $2.98 | -12.8% |
| 2026-01-29 | $4.47 | $4.40 | +1.6% |
| 2025-10-30 | $3.19 | $3.13 | +1.9% |
| 2025-07-31 | $3.13 | $3.07 | +2.0% |
| 2025-05-01 | $2.84 | $2.71 | +4.8% |
| 2025-01-28 | $4.01 | $3.87 | +3.6% |
Valuation Ratios
| P/E Ratio | 27.82 |
| Price / Book | 4.33 |
| EV / EBITDA | 19.02 |
| Dividend Yield | 1.29% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.32B | $12.44B | $13.60B | $14.88B | $14.35B | $17.11B | $18.45B | $20.50B | $22.59B | $25.12B |
| Cost of Revenue | $4.08B | $4.54B | $5.00B | $5.50B | $5.60B | $6.40B | $7.41B | $8.00B | $8.62B | $9.05B |
| Gross Profit | $7.25B | $7.90B | $8.60B | $9.38B | $8.75B | $10.71B | $11.04B | $12.49B | $13.98B | $16.07B |
| Research & Development | $715.0M | $787.0M | $862.0M | $971.0M | $905.0M | $1.13B | $1.23B | $1.29B | $1.41B | $1.58B |
| Selling, General & Admin | $3.95B | $4.35B | $4.63B | $5.02B | $4.82B | $5.81B | $6.08B | $6.92B | $7.50B | $8.65B |
| Operating Expenses | $4.67B | $5.14B | $5.50B | $5.99B | $5.72B | $6.95B | $7.31B | $8.21B | $8.92B | $11.18B |
| Operating Income | $2.58B | $2.77B | $3.10B | $3.39B | $3.03B | $3.76B | $3.73B | $4.28B | $5.06B | $4.89B |
| EBITDA | $2.69B | $2.95B | $3.34B | $3.63B | $3.08B | $3.61B | $4.02B | $5.06B | $4.94B | $6.31B |
| Interest Expense | $228.0M | $247.0M | $264.0M | $287.0M | $315.0M | $337.0M | $337.0M | $356.0M | $396.0M | $607.0M |
| Pre-tax Income | $1.92B | $2.06B | $2.36B | $2.56B | $1.95B | $2.28B | $2.68B | $3.67B | $3.49B | $4.51B |
| Income Tax | $274.0M | $1.04B | -$1.20B | $479.0M | $355.0M | $287.0M | $325.0M | $508.0M | $499.0M | $1.27B |
| Net Income | $1.65B | $1.02B | $3.55B | $2.08B | $1.60B | $1.99B | $2.36B | $3.17B | $2.99B | $3.25B |
| EPS | $4.40 | $2.73 | $9.50 | $5.57 | $4.26 | $5.29 | $6.23 | $8.34 | $7.86 | $8.49 |
| EPS (Diluted) | $4.35 | $2.68 | $9.34 | $5.48 | $4.20 | $5.22 | $6.17 | $8.25 | $7.76 | $8.40 |
| Shares Outstanding (Diluted) | $378.5M | $380.1M | $380.3M | $379.9M | $380.3M | $382.3M | $382.2M | $383.7M | $385.6M | $382.2M |
Price
| Price | $275.12 |
| Market Cap | $105.5B |
| Exchange | NYSE |
| Country | US |
Related companies: AMGN · BSX · DHR · GILD · HCA · MCK · MDT
Explore sector: Healthcare · Medical - Devices
More sections of SYK: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks